A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.

1. Kremer, J.M.
2. Cohen, S.
3. Wilkinson, B.E.
4. Connell, C.A.
5. French, J.L.
6. Gomez-Reino, J.
7. Gruben, D.
8. Kanik, K.S.
9. Krishnaswami, S.
10. Pascual-Ramos, V.
11. Wallenstein, G.
12. Zwillich, S.H.